TUM-affiliated UVC Partners has raised a third fund from limited partners including Lanxess to invest in industrial technologies, business-to-business software and mobility.

Insurer MACSF has taken part in round for patient data tool provider Savana, which will use the cash to expand to the US market.

Evotec and Boehringer Ingelheim Venture Fund returned in a $25.9m round for the autoimmune disease drug developer having first invested three years ago.

Topas Therapeutics, which is exploiting University of Hamburg research, has pocketed $26m in its series B round.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The commercialisation firm remains content with its position despite revenues drying up following its big exit from Virginia Tech's HawkEye 360 last year.

Five years after being co-founded by UCL researchers, Ori Biotech has brought its overall funding to $41m.

The electric bus and van developer has added cash from funds managed by BlackRock to money raised from Hyundai, Kia and UPS in January.

Novartis Venture Fund and Novo Seeds co-led a $10.4m round for oncology therapy developer Rappta on behalf of corporate parents Novartis and Novo.